Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
MRNA | NASDAQ | USD | Real-time | |
MRNA | Mexico | MXN | Delayed | |
MRNA | Milan | EUR | Real-time | |
0QF | Frankfurt | EUR | Delayed | |
0QF | TradeGate | EUR | Delayed | |
0QF | Xetra | EUR | Delayed | |
MRNAm | Buenos Aires | ARS | Delayed | |
M1RN34 | B3 | BRL | Delayed | |
MRNA | Vienna | EUR | Real-time | |
MRNA_KZ | KASE | USD | Delayed | |
MRNA | Lima | USD | Delayed |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Noubar B. Afeyan | 60 | 2010 | Co-Founder, Independent Non Executive Chairman & Member of Technology Advisory Board |
Stephane Bancel | 50 | 2011 | CEO & Director |
Melissa J. Moore | - | 2016 | Member of Scientific Advisory Board |
Jack W. Szostak | - | 2014 | Chairman of Scientific Advisory Board |
Richard C. Willson | - | 2014 | Member of Technology Advisory Board |
Fred E. Regnier | - | 2014 | Member of Technology Advisory Board |
John G. Aunins | 63 | 2014 | Member of Technology Advisory Board |
James R. Swartz | - | 2014 | Member of Technology Advisory Board |
Elizabeth G. Nabel | 72 | 2021 | Independent Director |
Elizabeth Edith Tallett | 74 | 2020 | Independent Director |
Ulrich H. von Andrian-Werburg | - | - | Member of Scientific Advisory Board |
Francois Nader | 67 | 2019 | Independent Non Executive Director |
Robert S. Langer | 75 | 2010 | Member of Scientific Advisory Board |
Ron Eydelloth | - | - | Member of Scientific Advisory Board |
Paul L. Sagan | 65 | 2018 | Independent Non Executive Director |
Sandra J. Horning | 75 | 2020 | Independent Director |
Rachel Green | - | - | Member of Scientific Advisory Board |
Michael Diamond | - | - | Member of Scientific Advisory Board |
Shah Abbas Hussain | 59 | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review